A clinic-responder-derived defined microbial consortium enhances anti-PD-1 immunotherapy efficacy in mice - PubMed
3 days ago
- #immunotherapy
- #microbiome
- #cancer
- A defined microbial consortium (RCom) of 15 bacterial species was developed from responder patient feces to enhance anti-PD-1 immunotherapy efficacy.
- RCom improves anti-tumor activity by increasing CD8+ T cell infiltration and cytotoxic function in tumor models.
- The consortium is stable, cooperative, and produces immunomodulatory metabolites, aiding in overcoming anti-PD-1 resistance.
- RCom shows potential as an adjuvant to improve responsiveness to anti-PD-1 therapy in cancer patients.
- The study was supported by multiple grants from the National Natural Science Foundation of China.